Nr. 205 etter markedsverdi
Euronext Growth Oslo · Helse og bioteknologi
8,02 kr
0,00 % i dag
Siste registrerte kurs: 13. okt., 15:29. Hentet: 14. okt., 02:26. Tid i Oslo. Kilde: Yahoo Finance. Kursene kan være forsinket.
616,7 mill. kr
2 957
−2,67 %
Siste 12 måneder · tall i NOK
Kilde: Yahoo Finance. Ikke en anbefaling fra oss.
Lytix Biopharma ASA er et selskap innen helse og bioteknologi notert på Euronext Growth Oslo med tickeren LYTIX. Hovedkontoret ligger i Oslo, Norge. Selskapet har 14 ansatte.
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.
Beskrivelse på engelsk fra Yahoo Finance.
Lytix Biopharma ASA: Grant of share options to management and key personnel
Lytix Biopharma ASA: Mandatory notification of trade by primary insider
Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining Milestone
FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma
Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma
Lytix Biopharma: Invitation to the Q2 2026 Results Presentation
Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Lytix Biopharma ASA: Grant of share options to management and key personnel
Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances
Siste tilgjengelige kurs for Lytix Biopharma ASA (LYTIX) er 8,02 kr, en endring på 0,00 % siste handelsdag. Kilde: Yahoo Finance. Kursene på Finansparken kan være forsinket med 15 minutter eller mer.
Lytix Biopharma ASA er notert på Euronext Growth Oslo med tickeren LYTIX. ISIN-koden er NO0010405780. Aksjen kan handles gjennom banker og nettmeglere som tilbyr handel på Oslo Børs.
Markedsverdien til Lytix Biopharma ASA er 616,7 mill. kr, beregnet som aksjekursen ganget med antall utestående aksjer. Det gjør selskapet til nummer 205 av 293 aksjer i Oslo målt etter markedsverdi.
Lytix Biopharma ASA er plassert i sektoren Helse og bioteknologi (bransje: Biotechnology). På sektorsiden finner du alle aksjer i samme sektor.
